CardioNova recruits first patient in Phase I/IIa clinical trial of AHRO-001 aimed at treatment of dyslipidemia and prevention of atherosclerosis

Skolkovo Biomedical Cluster Resident "CardioNova", founded with investments from Maxwell Biotech Venture Fund founded with the participation of RVC, announced today enrollment of the first volunteers with mild to moderate hyperlipidemia in a randomized, double-blind placebo controlled Phase I/IIa clinical trial. The study is aimed to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a short-term reception of the lead compound AHRO-001. Approximately 70 patients will take part in this trial.
During the clinical trial will be studied the interaction between the projected drug AHRO-001 and atorvastin, the current “gold standard” in dyslipidemia therapy. The trial will be held in two Moscow study centers.
Cardiovascular diseases remain the biggest cause of deaths worldwide. One of the main factors for cardiovascular pathologies progression is dyslipidemia (increase in cholesterin level) that results in vessel arterial sclerotic disease. As a result, the risk for such acute ischemic conditions as myocardial infarction, apoplectic attack, as well as limb ischemia, increases considerably.
Preclinical studies, conducted in partnership with AtheroNova, a public US company, demonstrated that use of AHRO-001 resulted not only to a significant reduction in cholesterol levels, but also induced significant regression of atherosclerotic plaques reduction (by up to 94%) in the various vessels. No currently marketed drug has evidence of so strong potency in plaque regression. 

Andrey Boldyrev, CEO of “CardioNova”: “We are delighted that after the preclinical studies, which have shown safety and efficacy of AHRO-001, this clinical trial has started. The successful accomplishment of Phase I/IIa clinical trial can afford the company to move to the next efficacy phase of studies in patients, suffering from cardiovascular diseases”. 

About CardioNova
"CardioNova", Ltd is a private biotechnology company, founded in 2011 to develop and launch into the Russian market innovative products to treat cardiovascular disease. Since December 2011 “CardioNova” has become a resident of Skolkovo Biomed Cluster. The first product (AHRO-001) is aimed at treatment and prevention of atherosclerosis dysplipidemia and developed in the framework of international cooperation with public biotech company AtheroNova, Inc. (OTC: AHRO).
About Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for innovative biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts. The Group includes 10 innovative biotechnological projects, developing in the portfolio companies: Oncomax, Photonics, Metamax, Infectex, NeuroMax, CardioNova, Hepatera, Osteros Biomedica, Eleventa.   All the group’s companies are the residents of the Biomed Cluster at Skolkovo Innovation Center and 5 of them are members of the Technology Platform “The Medicine of the Future”. 
For further information, please contact
Anna Sitnikova, Chief public relations Expert “Maxwell Biotech Group”
Tel. (495) 411-6992
About Russian Venture Company
RVC is a government fund of funds and a development institute of the Russian Federation, one of Russia's key tools in building its own national innovation system.
RVC was established by Russian Government on June 7, 2006 (Order No. 838-r). Its mission is to encourage Russia’s own VC industry and boost capital of VC funds. RVC’s role is that of a government fund of venture capital funds channeling public incentives to venture capital and financial support to the hi-tech sector, and of a Russian VC industry development institution.
RVC’s authorized capital — RUB 30 011 320 700 (about US$ 983.2 mln) — is 100% owned by the Federal Agency for State Property Management (Rosimuschestvo). RVC has backed 12 funds to a total capitalization of RUB 26.1 bln, its share amounting to RUB 16 bln. As on January 2013, RVC backed funds run a portfolio of 139 companies, invested capital totaling more than RUB 12.1 bln. 
For further information, please contact
Tel. (495) 411-6992


Anna Sitnikova,
Chief Public Relations Expert at Maxwell Biotech Group;
Tel.: +7 (495) 411-6992


Search form